News Image

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

Provided By GlobeNewswire

Last update: May 20, 2025

There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening

Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers

Read more at globenewswire.com

WEREWOLF THERAPEUTICS INC

NASDAQ:HOWL (5/30/2025, 8:01:42 PM)

After market: 1.17 -0.04 (-3.31%)

1.21

-0.07 (-5.47%)



Find more stocks in the Stock Screener

HOWL Latest News and Analysis

ChartMill News Image11 days ago - ChartmillTop movers in Tuesday's after hours session

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Mentions: NCI CRI EYEN SYTA ...

Follow ChartMill for more